Page 20 - Heca News Today

Britain recruited a record number of international nurses in the last financial year to plug hospital staffing shortages, with as many as 10% coming from so-called "red-list" countries where health staff should not be actively recruited.

Novo Nordisk said on Monday data from a late-stage trial showed an oral version of its drug semaglutide for weight loss helped overweight or obese adults lose on average between 15-17% of their body weight, comparable to its Wegovy injection.

Ironwood Pharmaceuticals Inc said on Monday it would buy Switzerland-based drug developer VectivBio Holding AG for $1.15 billion, adding a promising treatment for digestive disorders to its portfolio.

A shortage of cholera vaccines is likely to last until 2025 as outbreaks surge worldwide, a global vaccine alliance said on Monday, days after the World Health Organization warned that the short-term outlook for controlling the disease was bleak.

Governments should consider vaccinating birds against bird flu to avoid the virus - which has already killed hundreds of millions of birds and infected mammals worldwide - turning into a new pandemic, the head of the World Animal Health Organisation (WOAH) said.

Google on Friday defeated a lawsuit brought on behalf of 1.6 million people over medical records provided to the U.S. tech giant by a British hospital trust.

The U.S. Food and Drug Administration (FDA) has cleared Thermo Fisher Scientific Inc's test, the first of its kind in the country, to detect women with risk of severe preeclampsia, the company said on Friday.

Former Italian Prime Minister Silvio Berlusconi smiled from a car as he left Milan's San Raffaele hospital on Friday, returning home after six weeks of treatment for a lung infection linked to chronic leukaemia.

The U.S. Food and Drug Administration has approved AbbVie Inc and Danish drugmaker Genmab's blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said on Friday.

The U.S. Food and Drug Administration on Friday approved Krystal Biotech Inc's first-of-its kind topical gene therapy for patients with a genetic skin disorder, sending its shares up 7% in afternoon trading.